{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Eye+Disease&page=2", "query": { "condition": "Genetic Eye Disease", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Eye+Disease&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-27T06:26:57.727Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01868997", "title": "Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Thyroid Associated Ophthalmopathies", "Thyroid-Associated Ophthalmopathy" ], "interventions": [ { "name": "teprotumumab", "type": "DRUG" }, { "name": "normal saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 88, "start_date": "2013-07", "completion_date": "2017-02-22", "has_results": true, "last_update_posted_date": "2024-12-17", "last_synced_at": "2026-06-27T06:26:57.727Z", "location_count": 11, "location_summary": "Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01868997" }, { "nct_id": "NCT05544578", "title": "Korean Translation and Validation of the K-HEPI in NYC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Disaster", "Vulnerable Populations" ], "interventions": [ { "name": "Nurses Taking On Readiness Measures (N- TORM)", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Hunter College of City University of New York", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2023-07-13", "completion_date": "2024-07-19", "has_results": false, "last_update_posted_date": "2024-08-15", "last_synced_at": "2026-06-27T06:26:57.727Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05544578" }, { "nct_id": "NCT04123626", "title": "A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Autosomal Dominant Retinitis Pigmentosa", "Eye Diseases", "Eye Diseases, Hereditary", "Retinal Dystrophies", "Retinal Disease", "Retinitis", "Vision Tunnel", "Vision Disorders" ], "interventions": [ { "name": "QR-1123", "type": "DRUG" }, { "name": "Sham procedure", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "ProQR Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2019-10-07", "completion_date": "2022-06-07", "has_results": false, "last_update_posted_date": "2022-05-06", "last_synced_at": "2026-06-27T06:26:57.727Z", "location_count": 5, "location_summary": "Aurora, Colorado • Gainesville, Florida • Lexington, Kentucky + 2 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Portland", "state": "Oregon" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04123626" }, { "nct_id": "NCT00020579", "title": "MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "entinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2001-03", "completion_date": "2008-10", "has_results": false, "last_update_posted_date": "2012-03-15", "last_synced_at": "2026-06-27T06:26:57.727Z", "location_count": 3, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00020579" }, { "nct_id": "NCT01663935", "title": "Vision Response to Dopamine Replacement", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Albinism", "Oculocutaneous Albinism" ], "interventions": [ { "name": "Levodopa/carbidopa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": 20, "start_date": "2012-10-17", "completion_date": "2018-04-12", "has_results": true, "last_update_posted_date": "2019-06-11", "last_synced_at": "2026-06-27T06:26:57.727Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01663935" }, { "nct_id": "NCT06112340", "title": "Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Thyroid Eye Disease", "Graves Orbitopathy", "Endocrine System Diseases", "Eye Diseases", "Thyroid Associated Ophthalmopathy", "Graves Ophthalmopathy", "Thyroid Diseases", "Orbital Diseases", "Proptosis", "IGF1R", "Exophthalmos", "Hashimoto" ], "interventions": [ { "name": "linsitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sling Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2023-10-11", "completion_date": "2026-06", "has_results": false, "last_update_posted_date": "2025-02-25", "last_synced_at": "2026-06-27T06:26:57.727Z", "location_count": 2, "location_summary": "Miami, Florida • Morgantown, West Virginia", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Morgantown", "state": "West Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06112340" }, { "nct_id": "NCT01403402", "title": "Congenital Muscle Disease Study of Patient and Family Reported Medical Information", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Congenital Muscular Dystrophy With ITGA7 (Integrin Alpha-7) Deficiency", "Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy and Abnormal Glycosylation of Dystroglycan With Severe Epilepsy)", "Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Fatty Liver and Infantile-onset Cataract Caused by TRAPPC11 Mutations)", "Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Hypoglycosylation of Dystroglycan)", "Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Hypoglycosylation of Dystroglycan and Epilepsy)", "Alpha-Dystroglycanopathy (Dystroglycanopathy, Congenital With or Without Mental Retardation (Formerly MDC1C))", "Alpha-Dystroglycanopathy (Fukuyama CMD)", "Alpha-Dystroglycanopathy (LGMDR09 FKRP Related (Formerly LGMD2I))", "Alpha-Dystroglycanopathy (LGMDR11 POMT1 Related (Formerly LGMD2K))", "Alpha-Dystroglycanopathy (LGMDR13 FKTN Related (Formerly LGMD2M))", "Alpha-Dystroglycanopathy (LGMDR14 POMT2 Related (Formerly LGMD2N))", "Alpha-Dystroglycanopathy (LGMDR15 POMGnT1 Related (Formerly LGMD2O))", "Alpha-Dystroglycanopathy (LGMDR19 GMPPB Related (Formerly LGMD2T))", "Alpha-Dystroglycanopathy (LGMDR20 ISPD Related (Formerly LGMD2U))", "Alpha-Dystroglycanopathy (LGMDR24 POMGnT2 Related)", "Alpha-Dystroglycanopathy (Muscle Eye Brain Disease (MEB))", "Alpha-Dystroglycanopathy (Walker Warburg Syndrome (WWS))", "Choline Kinase B Receptor - CHKB", "Collagen VI Related Disorders", "Collagen XII Related Disorders", "Congenital Muscular Dystrophy Not Otherwise Specified (Including Merosin Positive)", "Congenital Muscular Dystrophy With Cataracts and Intellectual Disability (MDCCAID)", "Congenital Muscular Dystrophy With Joint Hyperlaxity", "Congenital Muscular Dystrophy With Rigid Spine Related to ACTA1", "Emery-Dreifuss Muscular Dystrophy", "GOLGA2-related Congenital Muscle Dystrophy With Brain Involvement", "LMNA Related Disorders", "Merosin Deficient CMD (Full or Partial)", "Nesprin Related MD (SYNE1)", "SELENON Related Disorders (Previously Known as SEPN1)", "SELENON Related Myopathy (Aka SEPN1)", "Telethonin CMD", "Congenital Myasthenic Syndrome", "Limb-Girdle Muscular Dystrophy", "LGMDD01 - DNAJB6 (Formerly LGMD1D)", "LGMDD05 - Collagen VI Related Bethlem Myopathy (Dominant)", "LGMDR07 - Telethonin (TCAP) Related (Formerly LGMD2G)", "LGMDR08 - TRIM Related (Formerly LGMD2H)", "LGMDR09 - FKRP Related (Formerly LGMD2I)", "LGMDR10 - Titin (TTN) Related (Formerly LGMD2J)", "LGMDR11 - POMT1 Related (Formerly LGMD2K)", "LGMDR13 - Fukutin (FKTN) Related (Formerly LGMD2M)", "LGMDR14 - POMT2 Related (Formerly LGMD2N)", "LGMDR15 - POMGnT1 Related (Formerly LGMD2O)", "LGMDR16 - DAG1 Related Dystroglycanopathy (Formerly LGMD2P)", "LGMDR17 - Plectin (PLEC) Related (Formerly LGMD2Q)", "LGMDR18 - TRAPPC11 Related (Formerly LGMD2S)", "LGMDR19 - GMPPB Related (Formerly LGMD2T)", "LGMDR20 - ISPD Related (Formerly LGMD2U)", "LGMDR22 - Collagen VI Related Bethlem Myopathy (Recessive)", "LGMDR23 - LAMA2 Related", "LGMDR24 - POMGnT2 Related" ], "interventions": [], "intervention_types": [], "sponsor": "Cure CMD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 4000, "start_date": "2009-09", "completion_date": "2029-09", "has_results": false, "last_update_posted_date": "2021-08-09", "last_synced_at": "2026-06-27T06:26:57.727Z", "location_count": 1, "location_summary": "Lakewood, California", "locations": [ { "city": "Lakewood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01403402" }, { "nct_id": "NCT02415153", "title": "Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neurofibromatosis Type 1", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Visual Pathway Glioma", "Recurrent Primary Central Nervous System Neoplasm", "Refractory Primary Central Nervous System Neoplasm" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "20 Years", "sex": "ALL", "summary": "3 Years to 20 Years" }, "enrollment_count": 29, "start_date": "2015-07-14", "completion_date": "2020-05-27", "has_results": false, "last_update_posted_date": "2022-04-25", "last_synced_at": "2026-06-27T06:26:57.727Z", "location_count": 12, "location_summary": "Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02415153" }, { "nct_id": "NCT00001456", "title": "Clinical and Basic Investigations Into Hermansky-Pudlak Syndrome", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hermansky-Pudlak Syndrome (HPS)" ], "interventions": [], "intervention_types": [], "sponsor": "National Human Genome Research Institute (NHGRI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "115 Years", "sex": "ALL", "summary": "1 Month to 115 Years" }, "enrollment_count": 600, "start_date": "1995-11-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-06-27T06:26:57.727Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001456" }, { "nct_id": "NCT00000688", "title": "A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cytomegalovirus Retinitis", "HIV Infections" ], "interventions": [ { "name": "Ganciclovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 180, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2011-03-14", "last_synced_at": "2026-06-27T06:26:57.727Z", "location_count": 22, "location_summary": "San Diego, California • San Francisco, California • San Mateo, California + 14 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Mateo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000688" } ] }